Biovica completes 510(k) submission for DiviTum®TKa to the FDA

STOCKHOLM, Sept. 25, 2020 /PRNewswire/ --

Biovica, active in blood-based cancer diagnostics, today announced that the company has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA)....
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Friday, 25 September

Share |